Liv­er can­cer drug com­bo gets sec­ond FDA re­jec­tion over man­u­fac­tur­ing is­sues

The FDA has once again re­ject­ed HLB and Jiang­su Hen­grui Phar­ma­ceu­ti­cals’ drug com­bi­na­tion to treat the most com­mon form of liv­er can­cer.

Ko­re­an biotech HLB …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER